National news outlet
Compared on: Trial and patient counts and probable NAION cases in an analysis of GLP-1 clinical trials.
THE CLAIM · NOV 15, 2026
“An analysis of 126 clinical trials involving more than 134,000 patients identified 15 probable cases of NAION, including 10 among GLP-1 users and five among placebo recipients”
As reported by Shafiq Najib · Read the post
THE RECORD · NOV 10, 2026
“The agency proceeded to review 126 clinical trials involving over 134,200 patients and identified 15 probable NAION cases, including 10 among GLP-1 patients; five in patients receiving placebo; and none in patients who were on glucose-lowering medications that were not GLP-1.”
The Guardian · FDA warns of rare eye condition causing blindness from GLP-1 weight loss... · Read
THE RECORD
“There were 126 such trials for GLP-1 RAs included in the meta-analysis, including a total of 134,253 patients (78,217 GLP-1 RA users and 56,036 patients receiving a comparator) with 288,879 PY of exposure (156,947 PY for the GLP-1 RA users and 131,932 PY for the patients receiving a comparator).”
FDA Requires Safety Labeling Changes for GLP-1 RAs · Read
RECORD AGREES
The Guardian reported the FDA’s review and probable case counts on November 10, 2026. The FDA’s November 9 safety communication gives the trial and patient totals for its GLP-1 receptor agonist meta-analysis.




